In premenopausal women with idiopathic osteoporosis, lower bone formation rate is associated with higher body fat and higher IGF-1.

Szczegóły
Abstrakt

Tytuł:: In premenopausal women with idiopathic osteoporosis, lower bone formation rate is associated with higher body fat and higher IGF-1.
Autorzy:: Goetz TG; Columbia University Vagelos College of Physicians & Surgeons, New York, NY, USA.
Nair N; Department of Medicine, Columbia University Vagelos College of Physicians & Surgeons, NY, New York, USA.
Shiau S; Department of Biostatistics and Epidemiology, Rutgers School of Public Health, Piscataway, NJ, USA.
Recker RR; Department of Medicine, Creighton University Medical Center, Omaha, NE, USA.
Lappe JM; Department of Medicine, Creighton University Medical Center, Omaha, NE, USA.
Dempster DW; Department of Pathology and Cell Biology, Columbia University Vagelos College of Physicians & Surgeons, New York, NY, USA.
Zhou H; Regional Bone Center, Helen Hayes Hospital, West Haverstraw, NY, USA.
Zhao B; Department of Radiology, Columbia University Vagelos College of Physicians & Surgeons, New York, NY, USA.
Guo X; Department of Radiology, Columbia University Vagelos College of Physicians & Surgeons, New York, NY, USA.
Shen W; Department of Pediatrics, Columbia University Vagelos College of Physicians & Surgeons, New York, NY, USA.; Institute of Human Nutrition, Columbia University Irving Medical Center, New York, NY, USA.; Columbia Magnetic Resonance Research Center (CMRRC), Columbia University, New York, NY, USA.
Nickolas TL; Department of Medicine, Columbia University Vagelos College of Physicians & Surgeons, NY, New York, USA.
Kamanda-Kosseh M; Department of Medicine, Columbia University Vagelos College of Physicians & Surgeons, NY, New York, USA.
Bucovsky M; Department of Medicine, Columbia University Vagelos College of Physicians & Surgeons, NY, New York, USA.
Stubby J; Department of Medicine, Creighton University Medical Center, Omaha, NE, USA.
Shane E; Department of Medicine, Columbia University Vagelos College of Physicians & Surgeons, NY, New York, USA.
Cohen A; Department of Medicine, Columbia University Vagelos College of Physicians & Surgeons, NY, New York, USA. .
Źródło:: Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA [Osteoporos Int] 2022 Mar; Vol. 33 (3), pp. 659-672. Date of Electronic Publication: 2021 Oct 19.
Typ publikacji:: Journal Article
Język:: English
Imprint Name(s):: Original Publication: London, UK : Springer International, c1990-
MeSH Terms:: Bone Density Conservation Agents*/therapeutic use
Osteoporosis*/drug therapy
Osteoporosis*/etiology
Adipose Tissue ; Bone Density ; Female ; Humans ; Insulin-Like Growth Factor I ; Osteogenesis ; Teriparatide/therapeutic use
References:: Lancet Diabetes Endocrinol. 2014 Jul;2(7):581-92. (PMID: 24731664)
Osteoporos Int. 2011 Jun;22(6):1703-8. (PMID: 20827548)
Clin Orthop Relat Res. 1971 Oct;80:147-54. (PMID: 5133320)
J Clin Endocrinol Metab. 2010 Mar;95(3):1247-55. (PMID: 20080853)
J Pathol Bacteriol. 1967 Oct;94(2):275-91. (PMID: 6066476)
J Clin Endocrinol Metab. 2008 Oct;93(10):3785-93. (PMID: 18682511)
J Clin Invest. 1991 Apr;87(4):1241-50. (PMID: 1707060)
J Clin Endocrinol Metab. 2007 Apr;92(4):1542-8. (PMID: 17264177)
J Clin Endocrinol Metab. 2013 Jun;98(6):2562-72. (PMID: 23515452)
J Appl Physiol (1985). 2009 Feb;106(2):418-22. (PMID: 19095751)
J Clin Endocrinol Metab. 2001 Nov;86(11):5509-15. (PMID: 11701729)
J Clin Endocrinol Metab. 2009 Jun;94(6):2129-36. (PMID: 19318450)
J Bone Miner Res. 2010 Apr;25(4):757-68. (PMID: 19821771)
Endocr Dev. 2013;24:128-37. (PMID: 23392101)
J Bone Miner Res. 2005 Jun;20(6):962-70. (PMID: 15883636)
Curr Osteoporos Rep. 2014 Mar;12(1):82-9. (PMID: 24419863)
Calcif Tissue Int. 2010 Dec;87(6):485-92. (PMID: 20953593)
Diabetes Obes Metab. 2009 Apr;11(4):275-84. (PMID: 18671797)
Obesity (Silver Spring). 2011 Jan;19(1):49-53. (PMID: 20467419)
J Clin Endocrinol Metab. 1998 Feb;83(2):382-95. (PMID: 9467546)
J Bone Miner Res. 2013 Jan;28(1):2-17. (PMID: 23197339)
J Clin Endocrinol Metab. 2014 May;99(5):1675-86. (PMID: 24483154)
J Clin Endocrinol Metab. 1997 Sep;82(9):2799-805. (PMID: 9284699)
J Clin Endocrinol Metab. 2020 Oct 1;105(10):. (PMID: 32876328)
Ann Med Interne (Paris). 1998 Mar;149(2):77-81. (PMID: 11490528)
J Comput Assist Tomogr. 2006 Sep-Oct;30(5):777-83. (PMID: 16954927)
Endocrinology. 1990 Oct;127(4):1804-10. (PMID: 2401235)
Eur J Endocrinol. 2010 Aug;163(2):185-91. (PMID: 20501597)
J Clin Endocrinol Metab. 1995 Jan;80(1):153-9. (PMID: 7829604)
Osteoporos Int. 2002;13(4):337-41. (PMID: 12030549)
J Bone Miner Res. 2017 Jun;32(6):1267-1273. (PMID: 28218468)
Osteoporos Int. 2007 May;18(5):641-7. (PMID: 17139464)
Bone. 2022 Jan;154:116253. (PMID: 34743040)
J Clin Endocrinol Metab. 2013 Jul;98(7):2854-63. (PMID: 23666961)
Diabetes Care. 2004 Jun;27(6):1487-95. (PMID: 15161807)
Bone. 2011 Apr 1;48(4):748-54. (PMID: 21195217)
Biogerontology. 2001;2(3):165-71. (PMID: 11708718)
Osteoporos Int. 2015 Oct;26(10):2471-8. (PMID: 25986383)
Eur J Endocrinol. 2009 Nov;161 Suppl 1:S97-S106. (PMID: 19684058)
J Clin Endocrinol Metab. 2013 May;98(5):1971-81. (PMID: 23543660)
J Clin Endocrinol Metab. 2011 Oct;96(10):3095-105. (PMID: 21832117)
J Clin Pathol. 2002 Sep;55(9):693-8. (PMID: 12195001)
J Clin Endocrinol Metab. 2009 Sep;94(9):3387-93. (PMID: 19531595)
J Clin Endocrinol Metab. 2009 Nov;94(11):4351-60. (PMID: 19837923)
Eur J Endocrinol. 2006 Jul;155(1):79-90. (PMID: 16793953)
J Clin Endocrinol Metab. 2012 Aug;97(8):2782-91. (PMID: 22701013)
J Bone Miner Res. 2007 Nov;22(11):1798-807. (PMID: 17645402)
Grant Information:: P30 DK026687 United States DK NIDDK NIH HHS; R01 FD003902 United States FD FDA HHS; R03 AR064016 United States AR NIAMS NIH HHS
Contributed Indexing:: Keywords: Body composition; Bone biopsy; Bone turnover markers; Marrow adiposity; Premenopausal osteoporosis; Teriparatide
Substance Nomenclature:: 0 (Bone Density Conservation Agents)
10T9CSU89I (Teriparatide)
67763-96-6 (Insulin-Like Growth Factor I)
Entry Date(s):: Date Created: 20211019 Date Completed: 20220216 Latest Revision: 20230302
Update Code:: 20240105
PubMed Central ID:: PMC9927557
DOI:: 10.1007/s00198-021-06196-8
PMID:: 34665288
: Czasopismo naukowe

Full Text Finder

We examined serum IGF-1 in premenopausal IOP, finding relationships that were opposite to those expected: higher IGF-1 was associated with lower bone formation and higher body fat, and lower BMD response to teriparatide. These paradoxical relationships between serum IGF-1, bone, and fat may contribute to the mechanism of idiopathic osteoporosis in premenopausal women.
Introduction: Premenopausal women with idiopathic osteoporosis (IOP) have marked deficits in bone microarchitecture but variable bone remodeling. We previously reported that those with low tissue-level bone formation rate (BFR) are less responsive to teriparatide and have higher serum IGF-1, a hormone anabolic for osteoblasts and other tissues. The IGF-1 data were unexpected because IGF-1 is low in other forms of low turnover osteoporosis-leading us to hypothesize that IGF-1 relationships are paradoxical in IOP. This study aimed to determine whether IOP women with low BFR have higher IGF-1 and paradoxical IGF-1 relationships in skeletal and non-skeletal tissues, and whether IGF-1 and the related measures predict teriparatide response.
Methods: This research is an ancillary study to a 24 month clinical trial of teriparatide for IOP. Baseline assessments were related to trial outcomes: BMD, bone remodeling.
Subjects: Premenopausal women with IOP(n = 34); bone remodeling status was defined by baseline cancellous BFR/BS on bone biopsy.
Measures: Serum IGF-1 parameters, compartmental adiposity (DXA, CT, MRI), serum hormones, and cardiovascular-risk-markers related to fat distribution.
Results: As seen in other populations, lower BFR was associated with higher body fat and poorer teriparatide response. However, in contrast to observations in other populations, low BFR, higher body fat, and poorer teriparatide response were all related to higher IGF-1: IGF-1 Z-score was inversely related to BFR at all bone surfaces (r = - 0.39 to - 0.46; p < 0.05), directly related to central fat (p = 0.05) and leptin (p = 0.03). IGF-1 inversely related to 24 month hip BMD %change (r = - 0.46; p = 0.01).
Conclusions: Paradoxical IGF-1 relationships suggest that abnormal or atypical regulation of bone and fat may contribute to osteoporosis mechanisms in premenopausal IOP.
(© 2021. International Osteoporosis Foundation and National Osteoporosis Foundation.)

Informacja